PKO Investment Management Joint Stock Co Buys 15,000 Shares of Pfizer Inc. (NYSE:PFE)

PKO Investment Management Joint Stock Co raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 19.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 94,000 shares of the biopharmaceutical company's stock after purchasing an additional 15,000 shares during the period. PKO Investment Management Joint Stock Co's holdings in Pfizer were worth $2,382,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Bfsg LLC raised its position in shares of Pfizer by 1.4% in the 1st quarter. Bfsg LLC now owns 184,709 shares of the biopharmaceutical company's stock worth $4,681,000 after acquiring an additional 2,514 shares in the last quarter. Cardinal Capital Management raised its position in shares of Pfizer by 5.7% in the 1st quarter. Cardinal Capital Management now owns 95,064 shares of the biopharmaceutical company's stock worth $2,409,000 after acquiring an additional 5,149 shares in the last quarter. Chicago Capital LLC raised its position in shares of Pfizer by 38.8% in the 1st quarter. Chicago Capital LLC now owns 97,375 shares of the biopharmaceutical company's stock worth $2,467,000 after acquiring an additional 27,206 shares in the last quarter. Vicus Capital raised its position in shares of Pfizer by 10.0% in the 1st quarter. Vicus Capital now owns 11,639 shares of the biopharmaceutical company's stock worth $295,000 after acquiring an additional 1,059 shares in the last quarter. Finally, Inscription Capital LLC bought a new position in shares of Pfizer in the 1st quarter worth approximately $1,060,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PFE. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Stock Down 0.5%

PFE traded down $0.13 during trading on Wednesday, hitting $23.88. 37,055,113 shares of the company's stock traded hands, compared to its average volume of 41,246,616. The stock has a market capitalization of $135.74 billion, a price-to-earnings ratio of 17.30, a PEG ratio of 0.87 and a beta of 0.57. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company's 50 day simple moving average is $23.14 and its two-hundred day simple moving average is $24.93.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period last year, the business posted $0.82 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.20%. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.